Study Details
A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants with Duchenne Muscular Dystrophy (DMD)
Clinicaltrials.gov ID
Astellas Study ID
0367-CL-0102
EudraCT ID
N/A
Condition
Duchenne Muscular Dystrophy (DMD)
Phase
Phase 1
Age
8 Years - 16 Years
Sex
Male
Product
ASP0367
Type
Interventional
Trial Dates
Feb 2021 - Sep 2022
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment number
8
A Randomized, Double Blind, Placebo-Controlled Phase 1b Study With Open-Label Extension to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Patients with Duchenne Muscular Dystrophy (DMD)
Study summary
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants with Duchenne Muscular Dystrophy (DMD)? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Children's Hospital of The King's Daughters
Norfolk, United States, 23507
Children's Hospital of Richmond at VCU
Richmond, United States, 23219
University of California Davis Health
Sacramento, United States, 95817
University of Kansas Medical Center
Kansas city, United States, 66160
UMass Memorial Medical Center
Worcester, United States, 01655
University of Minnesota
Minneapolis, United States, 55455
Children's Hospital Los Angeles
Los Angeles, United States, 90027
Kennedy Krieger Institute
Baltimore, United States, 21201
Children's Hospital of Philadelphia
Philadelphia, United States, 19104